Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT.
Peyre M, Sicre de Fontbrune F, Berceanu A, Benjemia L, Castelle M, D'Aveni M, Marçais A, Kaphan E, Bulabois CE, Sirvent A, Rohrlich PS, Coiteux V, Chantepie S, Nguyen-Quoc S, Peffault de Latour R, Coppo P. Peyre M, et al. Among authors: coiteux v. Bone Marrow Transplant. 2024 Jul;59(7):1034-1036. doi: 10.1038/s41409-024-02279-2. Epub 2024 Apr 11. Bone Marrow Transplant. 2024. PMID: 38605146 No abstract available.
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Guilhot F, et al. Among authors: coiteux v. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483613 Clinical Trial.
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)].
Rea D, Cayssials E, Charbonnier A, Coiteux V, Etienne G, Goldwirt L, Guerci-Bresler A, Huguet F, Legros L, Roy L, Nicolini FE. Rea D, et al. Among authors: coiteux v. Bull Cancer. 2024 Jan;111(1):87-96. doi: 10.1016/j.bulcan.2023.10.010. Epub 2023 Dec 11. Bull Cancer. 2024. PMID: 38087729 Free article. Review. French.
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, Penot A, Quittet P, Cony-Makhoul P, Saad A, Bastie JN, Hacini M, Coiteux V, Uzunov M, Roy L, Le Clech L, Berger M, Agneray AM, Messas E, Etienne G, Turhan A, Nicolini FE, Rousselot P. Huguet F, et al. Among authors: coiteux v. Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19819. Online ahead of print. Br J Haematol. 2024. PMID: 39506529
[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)].
Hamzy F, Chevallier P, Bruno B, Coiteux V, El Kababri M, Ibrahim A, Oudrhiri A, Yakoub-Agha I, Bekadja MA. Hamzy F, et al. Among authors: coiteux v. Bull Cancer. 2024 Oct 18:S0007-4551(24)00335-7. doi: 10.1016/j.bulcan.2024.09.001. Online ahead of print. Bull Cancer. 2024. PMID: 39426858 French.
[Preventing relapse of acute leukemias and myelodysplastic syndromes in post-allograft transplantation: Prophylactic and preemptive strategies (SFGM-TC)].
Coiteux V, Abellan I, Ahmad I, Boisnard A, Busquet C, Ceballos P, Coman T, Godin S, Hermet É, Marcais A, Mamez AC, Quessar A, Souchet L, Magro L, Simon N. Coiteux V, et al. Bull Cancer. 2024 Sep 5:S0007-4551(24)00277-7. doi: 10.1016/j.bulcan.2024.06.015. Online ahead of print. Bull Cancer. 2024. PMID: 39242256 French.
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Srour M, Alsuliman T, Labreuche J, Bulabois CE, Chevallier P, Daguindau E, Forcade E, François S, Guillerm G, Coiteux V, Turlure P, Beguin Y, Yakoub-Agha I, Magro L. Srour M, et al. Among authors: coiteux v. Bone Marrow Transplant. 2023 Apr;58(4):401-406. doi: 10.1038/s41409-022-01898-x. Epub 2023 Jan 9. Bone Marrow Transplant. 2023. PMID: 36624161 Free article. Clinical Trial.
The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
Sourisseau M, Faure E, Béhal H, Chauvet P, Srour M, Capes A, Coiteux V, Magro L, Alfandari S, Alidjinou EK, Simon N, Vuotto F, Karam M, Faure K, Yakoub-Agha I, Beauvais D. Sourisseau M, et al. Among authors: coiteux v. Blood Adv. 2023 Mar 14;7(5):856-865. doi: 10.1182/bloodadvances.2022008667. Blood Adv. 2023. PMID: 36350752 Free PMC article.
109 results